NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock



Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 2023 | | 2022 | | 2021 | |
|--------------------------------|----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 25,654,333,000 | | 34,149,132,000 | | 41,655,955,000 | |
| Common stock capital | | 694,361,000 | | 823,428,000 | | 820,946,000 |
| Fixed assets | 61,729,135,000 | | 78,507,846,000 | | 82,154,750,000 | |
| Equity capital of a company | | 39,347,137,000 | | 54,978,159,000 | | 61,796,015,000 |
| Cash and cash equivalents | 11,272,218,000 | | 6,954,728,000 | | 11,304,638,000 | |
| Accrued liabilities | | 2,802,694,000 | | 3,079,065,000 | | 4,279,671,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 22,211,143,000 | | 26,512,531,000 | | 27,524,019,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 25,825,188,000 | | 31,166,287,000 | | 34,490,672,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 1,004,088,000 | | 1,459,965,000 | | 1,343,946,000 |
| Total assets | 87,383,469,000 | 87,383,469,000 | 112,656,978,000 | 112,656,978,000 | 123,810,706,000 | 123,810,706,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 76,057 | 101,703 | 104,323 |
| Equity ratio | 45.11% | 48.87% | 50.03% |
| Debt-equity ratio | 121.69% | 104.63% | 99.86% |

Others

| | 2023 | 2022 | 2021 |
|------------------|-------|--------|--------|
| Tax Expense Rate | 6.03% | 16.90% | 19.62% |

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock

| Income statement | | | |
|--|----------------|----------------|----------------|
| | 2023 | 2022 | 2021 |
| Turnover | 40,834,735,000 | 48,273,766,000 | 47,199,917,000 |
| Net income | 7,699,648,000 | 6,642,477,000 | 21,961,593,000 |
| EBIT | 8,684,331,929 | 8,887,261,883 | 10,954,364,535 |
| Operating income before taxes | 8,210,082,000 | 8,003,445,000 | 9,872,248,000 |
| Cash Flow | 12,992,707,000 | 13,596,306,000 | 13,778,909,000 |
| Net interest income | -223,764,000 | -627,477,000 | -766,155,000 |
| Research and development expenses | 7,389,613,000 | 8,484,798,000 | 8,722,101,000 |
| Income taxes | 495,157,000 | 1,352,372,000 | 1,937,330,000 |
| Result from investments in subsidaries, associates and other | -11,682,000 | -8,595,000 | 14,023,932,000 |
| Revenues per employee | 552,842 | 488,752 | 465,878 |

| Mambar of the administrative heard | |
|-------------------------------------|---|
| | |
| Member of the administrative board | |
| Chairman of the administrative boar | |
| | Member of the administrative board |

| Members of Management Board | | | |
|-----------------------------|-------------------------------|--|--|
| | | | |
| Vasant (Vas) Narasimhan | Chairman of Managing Board | | |
| Klaus Moosmayer | Member of Executive Committee | | |
| Steffen Lang | Member of Executive Committee | | |
| Aharon Gal | Member of Executive Committee | | |
| Fiona H. Marshall | Member of Executive Committee | | |
| Harry Kirsch | Member of Executive Committee | | |
| Karen Hale | Member of Executive Committee | | |
| Kees Roks | Member of Executive Committee | | |
| Lutz Hegemann | Member of Executive Committee | | |
| Michelle Weese | Member of Executive Committee | | |
| Patrick Horber | Member of Executive Committee | | |
| Rob Kowalski | Member of Executive Committee | | |
| Shreeram Aradhye | Member of Executive Committee | | |
| Victor Bulto | Member of Executive Committee | | |